Revvity Inc. Announces Strategic Collaboration with Profluent to Enhance Gene Editing Platform

Reuters

Sep 22, 2025

Revvity Inc. Announces Strategic Collaboration with Profluent to Enhance Gene Editing Platform

Revvity Inc. has announced a strategic collaboration with Profluent to enhance its gene editing capabilities. The partnership combines Profluent's AI-engineered enzymes with Revvity's Pin-point base editing platform, providing customers with access to a comprehensive base editing toolkit. This collaboration aims to facilitate the development of novel gene editing therapies by offering a customizable and therapeutically relevant system. By integrating Profluent's proteins, Revvity's Pin-point platform seeks to expand the potential to address a wider range of disease-related mutations. The collaboration reflects both companies' commitment to advancing base editing technologies and accelerating the creation of life-changing therapies. Revvity plans to present the new AI-enhanced adenine deaminase Pin-point system at the ESGCT 2025 Annual Congress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922513581) on September 22, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2569784899"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569784899\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569784899?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-22 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569784899","market":"fut","top_or_hot":-1,"title":"Revvity Inc. Announces Strategic Collaboration with Profluent to Enhance Gene Editing Platform","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Revvity Inc. Announces Strategic Collaboration with Profluent to Enhance Gene Editing Platform\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Revvity Inc. has announced a strategic collaboration with Profluent to enhance its gene editing capabilities. The partnership combines Profluent's AI-engineered enzymes with Revvity's Pin-point base editing platform, providing customers with access to a comprehensive base editing toolkit. This collaboration aims to facilitate the development of novel gene editing therapies by offering a customizable and therapeutically relevant system. By integrating Profluent's proteins, Revvity's Pin-point platform seeks to expand the potential to address a wider range of disease-related mutations. The collaboration reflects both companies' commitment to advancing base editing technologies and accelerating the creation of life-changing therapies. Revvity plans to present the new AI-enhanced adenine deaminase Pin-point system at the ESGCT 2025 Annual Congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922513581) on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revvity Inc. Announces Strategic Collaboration with Profluent to Enhance Gene Editing Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevvity Inc. Announces Strategic Collaboration with Profluent to Enhance Gene Editing Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-22 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Revvity Inc. Announces Strategic Collaboration with Profluent to Enhance Gene Editing Platform\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Revvity Inc. has announced a strategic collaboration with Profluent to enhance its gene editing capabilities. The partnership combines Profluent's AI-engineered enzymes with Revvity's Pin-point base editing platform, providing customers with access to a comprehensive base editing toolkit. This collaboration aims to facilitate the development of novel gene editing therapies by offering a customizable and therapeutically relevant system. By integrating Profluent's proteins, Revvity's Pin-point platform seeks to expand the potential to address a wider range of disease-related mutations. The collaboration reflects both companies' commitment to advancing base editing technologies and accelerating the creation of life-changing therapies. Revvity plans to present the new AI-enhanced adenine deaminase Pin-point system at the ESGCT 2025 Annual Congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922513581) on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nNDL2wB4Hb:1","article_id":"2569784899","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569784899","pubTimestamp":1758542476,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Revvity Inc. has announced a strategic collaboration with Profluent to enhance its gene editing capabilities. The partnership combines Profluent's AI-engineered enzymes with Revvity's Pin-point base editing platform, providing customers with access to a comprehensive base editing toolkit. This collaboration aims to facilitate the development of novel gene editing therapies by offering a customizable and therapeutically relevant system. By integrating Profluent's proteins, Revvity's Pin-point platform seeks to expand the potential to address a wider range of disease-related mutations. The collaboration reflects both companies' commitment to advancing base editing technologies and accelerating the creation of life-changing therapies. Revvity plans to present the new AI-enhanced adenine deaminase Pin-point system at the ESGCT 2025 Annual Congress.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","RVTY":"REVVITY INC","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Revvity Inc.宣布与Profluent开展战略合作，增强基因编辑平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVTY":0.9},"content_text":"Revvity Inc. Announces Strategic Collaboration with Profluent to Enhance Gene Editing Platform\n    \n\n        Revvity Inc. has announced a strategic collaboration with Profluent to enhance its gene editing capabilities. The partnership combines Profluent's AI-engineered enzymes with Revvity's Pin-point base editing platform, providing customers with access to a comprehensive base editing toolkit. This collaboration aims to facilitate the development of novel gene editing therapies by offering a customizable and therapeutically relevant system. By integrating Profluent's proteins, Revvity's Pin-point platform seeks to expand the potential to address a wider range of disease-related mutations. The collaboration reflects both companies' commitment to advancing base editing technologies and accelerating the creation of life-changing therapies. Revvity plans to present the new AI-enhanced adenine deaminase Pin-point system at the ESGCT 2025 Annual Congress.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922513581) on September 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}